Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.

Cellular signalling - 1 May 2016

Wang Zhao-Tong, Chen Zhuo-Jia, Jiang Guan-Min, Wu Ying-Min, Liu Tao, Yi Yan-Mei, Zeng Jun, Du Jun, Wang Hong-Sheng

Abstract excerpt

There is an urgent need to investigate the potential targeted therapy approach for triple-negative breast cancer (TNBC). Our present study reveals that histone deacetylase inhibitors (HDACIs) suberoyl anilide hydroxamic acid (SAHA) and sodium butyrate (NaB) significantly inhibit cell proliferation, arrest cell cycle at G0/G1 phase, and induce mitochondrial related apoptosis of TNBC cells. Further, SAHA and NaB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Butyric Acid
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Hydroxamic Acids

Share to Triple Negative Breast Neoplasms

Share to Vorinostat

Share to YY1 Transcription Factor

Source

Identifiers

PMID: 26876786
DOI: 10.1016/j.cellsig.2016.02.006

Genes

HDAC8
HDAC6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.PMID 26876786Read ↗

Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

HDAC Inhibitors for the Therapy of Triple Negative Breast CancerSemantic proximity Read ↗

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast CancerSemantic proximity Read ↗

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Semantic proximity Read ↗

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 InhibitionSemantic proximity Read ↗

JAC1 Targets YY1-Mediated JWA/p38 MAPK Signaling to Inhibit Proliferation and Induce Apoptosis in TNBCSemantic proximity Read ↗

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast CancerSemantic proximity Read ↗

Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: A therapeutic targetSemantic proximity Read ↗

Transcription Factor YY1 Contributes to Tumor Growth by Stabilizing Hypoxia Factor HIF-1α in a p53-Independent MannerSemantic proximity Read ↗

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.Semantic proximity Read ↗

Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53Semantic proximity Read ↗

TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.